Bulletin
Investor Alert

press release

Oct. 27, 2021, 8:00 a.m. EDT

Intercept to Announce Third Quarter 2021 Financial Results on November 3, 2021

NEW YORK, Oct 27, 2021 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. /zigman2/quotes/202434567/composite ICPT -5.05% , a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2021 financial results prior to market open on Wednesday, November 3, 2021. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.

The conference call will be available on the investor page of our website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free domestic) or (315) 625-6894 (international) passcode 6266006. Archived webcasts will be available on Intercept's website for approximately two weeks.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn .

CONTACT

For more information about Intercept, please contact:

Investor inquiries: investors@interceptpharma.com

Media inquiries: media@interceptpharma.com

COMTEX_395888066/2471/2021-10-27T08:00:16

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/202434567/composite
US : U.S.: Nasdaq
$ 17.87
-0.95 -5.05%
Volume: 661,284
May 18, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$559.12 million
Rev. per Employee
$847,572
loading...

Partner Center

Link to MarketWatch's Slice.